1. Articles from biospace.com

  2. 1-24 of 128 1 2 3 4 5 6 »
    1. Ultragenyx Appoints Corsee Sanders, Ph.D., to Board of Directors

      Ultragenyx Appoints Corsee Sanders, Ph.D., to Board of Directors

      NOVATO, Calif., June 30, 2021 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc.(NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today announced the appointment of Corsee Sanders, Ph.D., to the Board of Directors...

      Read Full Article
    2. Imara Announces Appointment of Laura A. Williams, M.D., MPH to Board of Directors

      Imara Announces Appointment of Laura A. Williams, M.D., MPH to Board of Directors

      BOSTON, June 30, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin, today announced the election of Laura A. Williams, M.D., MPH to its Board of Directors...

      Read Full Article
    3. Trillium Therapeutics Appoints Catherine Mackey, Ph.D., to Its Board of Directors

      Trillium Therapeutics Appoints Catherine Mackey, Ph.D., to Its Board of Directors

      CAMBRIDGE, Mass., June 30, 2021 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced the appointment of pharmaceutical industry leader Catherine Mackey, Ph.D., to its Board of Directors...

      Read Full Article
    4. NeuBase Therapeutics Appoints Gerald J. McDougall to Board of Directors

      NeuBase Therapeutics Appoints Gerald J. McDougall to Board of Directors

      PITTSBURGH, May 12, 2021 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) ("NeuBase" or the "Company"), a biotechnology company accelerating the genetic revolution with a new class of precision genetic medicines, announced today the appointment of Gerald (Gerry) J. McDougall to the Company's Board of Directors...

      Read Full Article
    5. Graphite Bio Appoints Dr. Kristen Hege, Smital Shah and Dr. Jo Viney to Board of Directors

      Graphite Bio Appoints Dr. Kristen Hege, Smital Shah and Dr. Jo Viney to Board of Directors

      SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Graphite Bio., a clinical-stage, next-generation gene editing company focused on therapies that harness targeted gene integration to treat or cure serious diseases, today announced the appointments of Dr. Kristen Hege, Smital Shah and Dr. Jo Viney to its board of directors...

      Read Full Article
    6. Finch Therapeutics Appoints Susan E. Graf to Board of Directors

      Finch Therapeutics Appoints Susan E. Graf to Board of Directors

      SOMERVILLE, Mass., April 27, 2021 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery platform to develop a novel class of orally administered biological drugs, today announced that Susan E. Graf has joined Finch’s Board of Directors...

      Read Full Article
    7. Allena Pharmaceuticals Appoints Mark J. Fitzpatrick to its Board of Directors

      Allena Pharmaceuticals Appoints Mark J. Fitzpatrick to its Board of Directors

      NEWTON, Mass., April 07, 2021 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc.,  (NASDAQ: ALNA), a late-stage biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today announced the appointment of Mark J. Fitzpatrick to its board of directors...

      Read Full Article
    8. Mersana Therapeutics Announces Appointment of Allene Diaz to Board of Directors

      Mersana Therapeutics Announces Appointment of Allene Diaz to Board of Directors

      CAMBRIDGE, Mass., March 11, 2021 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc.. (Nasdaq: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced the appointment of Allene Diaz to its board of directors...

      Read Full Article
    1-24 of 128 1 2 3 4 5 6 »
  1. Categories

    1. BoardProspects Features:

      BoardBlogs, BoardKnowledge, BoardMoves, BoardNews, BoardProspects Announcements, BoardProspects CEO, CEO Blog, Competitor Corner, In the News, Member Report, Partner Publications, Question of The Week, Sponsored Content